

Edgar Filing: THERMAGE INC - Form FWP

THERMAGE INC  
Form FWP  
November 09, 2006

Filed Pursuant to Rule 433

Issuer Free Writing Prospectus dated November 9, 2006

Relating to Preliminary Prospectus dated November 3, 2006

Registration No. 333-136501

On November 9, 2006, Thermage, Inc. filed Amendment No. 5 to its Registration Statement on Form S-1 to update certain disclosures that had been provided in its preliminary prospectus dated November 3, 2006 relating to this offering. The following summarizes certain terms of the disclosure in the preliminary prospectus included in Amendment No. 5 to the Registration Statement that updates the disclosure in the preliminary prospectus dated November 3, 2006. A filed copy of our current registration statement is available via the following link:

<http://www.sec.gov/cgi-bin/browse-edgar?company=thermage&CIK=&filenum=&State=&SIC=&owner=include&action=getcompany>

<b>Common stock offered by us:</b>	6,000,000 shares (excluding option to purchase up to 900,000 additional shares to cover overallotments)
<b>Common stock to be outstanding after this offering:</b>	22,370,450
<b>Assumed initial public offering price per share:</b>	\$8.00 \$9.00 per share
<b>Net proceeds to us:</b>	Approximately \$45.1 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us and assuming a public offering price of \$8.50 per share, which is the mid-point of the range set forth above.
<b>Use of proceeds:</b>	The net proceeds that we will receive from the offering will be less than the estimated net proceeds set forth under the caption Use of Proceeds in the Preliminary Prospectus, which was based on an assumed initial offering price of \$12.00 per share.

As a result, we currently expect to use our net proceeds from this offering as follows:

approximately \$18 million for sales and marketing initiatives to support the ongoing commercialization of our ThermaCool system;

approximately \$8 million for research and development activities, including support of product development, regulatory and clinical study initiatives;

Edgar Filing: THERMAGE INC - Form FWP

\$5.0 million for repayment of our working capital line with GE Capital, \$2.5 million of which bears interest at 10.2% per annum and

is due in November 2008, and \$2.5 million of which bears interest at 10.6% per annum and is due in December 2008; and

the remainder for general corporate purposes.

We may use a portion of our net proceeds to acquire complementary products, technologies or businesses; however, we currently have no agreements or commitments to complete any such transaction and are not involved in negotiations to do so.

**Pro forma as adjusted balance sheet data:**

Based on the initial offering price of \$8.50 per share, the mid-point of the range assumed in this free writing prospectus, as of June 30, 2006, on a pro forma as adjusted basis, cash and cash equivalents would have been approximately \$55.3 million and, working capital would have been approximately \$56.3 million, total assets would have been approximately \$69.1 million, and total stockholders equity would have been approximately \$55.3 million.

**Pro forma as adjusted capitalization:**

Based on the initial offering price of \$8.50 per share, the mid-point of the range assumed in this free writing prospectus, as of June 30, 2006, on a pro forma as adjusted basis, additional paid-in capital would have been approximately \$99.9 million, total stockholders equity would have been approximately \$55.3 million and total capitalization would have been approximately \$59.1 million.

**Dilution:**

Based on the initial public offering price of \$8.50 per share, the mid-point of the range assumed in this free writing prospectus, our pro forma as adjusted net tangible book value after this offering would have been \$55.3 million, as of June 30, 2006. This represents an immediate increase in pro forma as adjusted net tangible book value of \$1.85 per share to our existing stockholders and an immediate dilution in pro forma as adjusted net tangible book value of \$6.03 per share to investors participating in this offering at the initial public offering price. Investors purchasing shares of common stock in this offering will have purchased approximately 27% of our outstanding common stock immediately following the completion of this offering and will have contributed approximately 51% of the total consideration paid for our common stock.

**Option Grants in Last Fiscal Year:**

The following table shows information regarding stock options granted to the executive officers. The potential realizable value is based on the assumption that our common stock appreciates at the annual rate shown, compounded annually, from the date of grant until the expiration of the ten-year term of the option. Potential realizable values are computed by multiplying the number of shares of common stock underlying each option by \$8.50 per share, the midpoint of the range in this free writing prospectus; assuming that the total stock value derived from that calculation compounds at the annual 5% or 10% rate shown in the table for the entire ten-year term of the option; and subtracting from that result the total option exercise price.

**2005 Option Grants**

Name	Potential Realizable Value	
	at Assumed Annual Rates of	
	Stock Price Appreciation for	
	Option Term	
	5%	10%
Stephen J. Fanning	\$ 6,399,643	\$ 11,730,427
Laureen DeBuono		
Douglas W. Heigel	39,382	72,187
Richard J. Meader		
Gary L. Wilson	738,420	1,353,511
Robert F. Byrnes	118,147	216,562

**Aggregated Option Exercises in 2005 and Year-End Option Values:**

The following table sets forth certain information with respect to option exercises in the year ended December 31, 2005 and the total value of options held by each executive officer as of December 31, 2005. The value realized upon the exercise of options and the value of the unexercised in-the-money options at year-end have been calculated using an assumed initial public offering price of \$8.50 per share, the midpoint of the range in this free writing prospectus, minus the applicable per share exercise price.

**2005 Aggregated Option Exercises and Year-End Values**

Name	Value of Unexercised In-the-Money Options at December 31, 2005	
	Exercisable	Unexercisable
Stephen J. Fanning	\$	\$ 2,925,000
Laureen DeBuono	2,035,000	
Douglas W. Heigel	560,856	429,102
Richard J. Meader	362,250	67,926
Gary L. Wilson	289,059	603,441
Robert F. Byrnes		

**Automatic Conversion of Preferred Stock and Warrants:**

On November 8, 2006, our Board of Directors and requisite majority of stockholders approved the amendment of the preferred stock automatic conversion provision contained in our Amended and Restated Certificate of Incorporation. As a result of this amendment, the automatic conversion feature that specifies a price of at least \$10.00 per share in an initial public offering will be removed from the automatic conversion terms of our convertible preferred stock. On that same date, the Board of Directors and holders of warrants approved the amendment of the exercise period provision of all outstanding warrants that were issued in connection with our Series C Preferred Stock financing. As a result of this amendment, the expiration term that specified a price of at least \$10.00 per share in an initial public offering was removed from the exercise period provision of such warrants.

Edgar Filing: THERMAGE INC - Form FWP

**The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at [www.sec.gov](http://www.sec.gov). Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling toll-free Merrill Lynch & Co., 4 World Financial Center, New York, New York 10080 (telephone: 866-500-5408).**